Recent data have implicated tumor necrosis factor (ligand) superfamily, member 4 (TNFSF4) gene variation in myocardial infarction in women; however, no prospective data are available on either incident arterial or venous disorders.
Vascular inflammation is a key component in the development and progression of cardiovascular disease (CVD) 3 and venous thromboembolism (VTE). Understanding of the processes that initiate and maintain inflammation has increased with the characterization of new disease pathways in the adaptive and innate immune systems. One such pathway is the receptorligand pair Ox40-Ox40 ligand (Ox40L), which has shown association with atherosclerosis in both mouse and human (1 ) . Interruption of the Ox40-Ox40L pathway attenuates atherogenesis in LDL receptor-deficient mice (2 ) .
Ox40L is a 34-kDa glycoprotein belonging to the tumor necrosis superfamily. The expression of Ox40L has been observed in T cells, B lymphocytes, vascular endothelial cells, and importantly, dendritic cells (3) (4) (5) . Cross-linking of Ox40L with Ox40 provides a T-cell costimulatory signal, resulting in increased proliferation and cytokine production (4, 5 ) . In addition, there is evidence that Ox40L inhibits interleukin (IL)-10 production and suppresses the function of IL-10 -producing T cells, which may be a unique function of Ox40L to regulate immunity and tolerance (2 ) . Attributable to the immunoregulatory role of this pathway, interactions between Ox40 and Ox40L have the po-tential to enhance inflammatory responses in atherosclerotic plaque.
Single nucleotide polymorphisms (SNPs) in the tumor necrosis factor (ligand) superfamily, member 4 (TNFSF4) 4 gene, encoding Ox40L, have been associated with increased risk of myocardial infarction (MI) in women (1 ) . In contrast, the role of inflammatory genes in VTE is less explored. More importantly, the long-term risk of thromboembolic events associated with TNFSF4 variants and, hence, their predictive power remain unknown. We therefore investigated the associations of 2 previously characterized TNFSF4 variants (-921CϾT and dbSNP rs3850641) with a) risk of incident arterial events using a prospective, casecohort design with 344 incident CVD cases and 2386 control participants drawn from the Women's Health Study (WHS) and b) VTE risk in men and women drawn from the Physicians' Health Study (PHS) cohort and the WHS cohort, respectively.
Materials and Methods

STUDY DESIGN
Physicians' Health Study. We employed a nested case-control design within the PHS, a randomized, double-blinded, placebo-controlled trial of aspirin and ␤-carotene initiated in 1982 among 22 071 male, predominantly white (Ͼ94%) U.S. physicians, 40 -84 years of age at study entry (6 ) . Before randomization, 14 916 participants provided an EDTA-anticoagulated blood sample, which was stored for genetic analysis. All participants were free of prior MI, stroke, transient ischemic attacks, deep venous thrombosis/pulmonary embolism (DVT/PE), and cancer at study entry. Yearly follow-up self-report questionnaires provided reliable updated information on newly developed diseases and the presence or absence of other cardiovascular risk factors. A history of cardiovascular risk factors, such as hypertension, diabetes, or hyperlipidemia, was defined by self-report of diagnosis at entry into the study. For all reported incident vascular events occurring after study enrollment, hospital records, death certificates, and autopsy reports were requested and reviewed by an end-points committee using standardized diagnostic criteria.
A diagnosis of DVT was confirmed by a positive report of venous ultrasound or venography, whereas the diagnosis of PE was confirmed in the presence of either a positive angiogram or a ventilation-perfusion scan with 2 or more mismatched defects. Idiopathic (primary/unprovoked) DVT/PE was defined as occurring in the absence of known malignancy, recent trauma, or surgery (7 ). For each case, a control matched by age, smoking history, and length of follow-up was chosen among those subjects who remained free of vascular diseases; 108 case-control pairs were identified for the present investigation, all white men.
The study was approved by the Brigham and Women's Hospital Institutional Review Board for Human Subjects Research.
Women's Health Study. We employed a case-cohort design within the WHS cohort, a recently completed randomized, double-blinded, placebo-controlled clinical trial of low-dose aspirin and vitamin E aimed at assessing the hypothesis of primary prevention of CVD and cancer in U.S. female healthcare professionals through this intervention (8 ) . Eligible participants were apparently healthy women, age 45 years or older, who were free of self-reported CVD or cancer at study entry (1992) (1993) (1994) (1995) , with follow-up for incident CVD through February 2005. At the time of enrollment, participants provided written informed consent; completed questionnaires on racial/ethnic status, demographic variables, medical history, medication use, dietary and lifestyle variables; and were asked to provide a blood sample.
Participants were followed for the composite end point of incident CVD (nonfatal MI, nonfatal ischemic stroke, coronary revascularization, or cardiovascular death) and the individual endpoints of nonfatal MI and nonfatal ischemic stroke. Medical records were obtained and reviewed for confirmation of events as described (8 ) . Deaths from cardiovascular causes were identified by reports from family members, postal authorities, and a search of the National Death Index and were confirmed by autopsy reports, death certificates, and medical records. For the composite endpoint of incident VTE (DVT/PE), medical records were obtained and reviewed for confirmation of events as described (9 ) . Deaths from vascular causes were identified by reports from family members, postal authorities, and a search of the National Death Index and were confirmed by autopsy reports, death certificates, and medical records.
The present case-cohort study consisted of white women who were not current smokers, and not hormone replacement therapy (HRT) users: 344 incident CVD cases (including 91 MI and 95 ischemic stroke) and 2254 subcohort controls were available for the arterial investigation; and 125 incident DVT/PE cases and 2269 subcohort controls were available for the venous investigation. 
SNP SELECTION AND GENOTYPE DETERMINATION
The rs3850641 SNP is positioned in intron 1 and was chosen for its strong association with MI in a previous study (1 ) . We also selected the Ϫ921CϾT variant, positioned in the TNFSF4 promoter, for its putative role in transcription regulation (10 ) . We determined genotype using a fluorescence-based allelic discrimination method (Applied Biosystems) (11 ) . Each 10-mL amplification reaction volume contained 1ϫ Universal Master Mix (ABgene Inc.) and 10 ng template DNA. Amplification reactions were carried out on an ABI 7900HT Sequence Detection System according to the manufacturer's specifications. To confirm genotype assignment, scoring was carried out by 2 independent observers. Discordant results (Ͻ1% of all scoring) were resolved by a joint reading, and if necessary, a repeat genotyping. In addition, quality control (duplicategenotyping) was performed on 5% randomly selected samples, and 100% concordance on genotype assignment was observed. Results were scored blinded as to case-control status.
STATISTICAL ANALYSIS
WHS.
We compared allele and genotype frequencies among cases and controls with values predicted by Hardy-Weinberg equilibrium using the 2 test. Hazard ratios (HRs) of total CVD, MI, ischemic stroke, or VTE associated with each polymorphism were calculated separately by a weighted Cox proportionalhazards analysis using Barlow's method (12, 13) with adjustment for age and further adjustment for traditional CVD risk factors or potential confounders [randomized treatment assignment, body mass index (BMI), history of hypertension (Ն140/90 mm Hg or on antihypertensive medications or physician's diagnosis), presence or absence of diabetes, hyperlipidemia [plasma cholesterol Ն6.21 mmol/L (Ն240 mg/dL)], and the use of hormone replacement therapy], assuming an additive, dominant, or recessive mode of inheritance. Because the TT-homozygote for Ϫ921CϾT was quite rare, analysis assuming a recessive model was not performed. We examined pairwise linkage disequilibrium (LD) as described by Devlin and Risch (14 ) and performed haplotype inference and frequency estimation using Phase v2.1.1 (15, 16 ) . In addition, we examined the relationship between haplotypes and each prespecified clinical endpoint (MI, or ischemic stroke) separately using a haplotype-based weighted Cox proportional-hazards analysis with baseline parameterization (17 ), adjusting for the same potential risk factors or confounders. For each HR, we calculated 95% CIs.
PHS.
We compared allele and genotype frequencies among cases and controls with values predicted by Hardy-Weinberg equilibrium using the 2 test. Relative risks of VTE associated with each genotype were calculated separately by conditional logistic regression analysis conditioning on the matching by age, smoking status, and length of follow-up since randomization and further controlling for randomized treatment assignment, history of hypertension, diabetes, and BMI, assuming additive, dominant, or recessive mode of inheritance. Because the TT-homozygote for Ϫ921CϾT was quite rare, analysis assuming a recessive model was not performed. We examined pairwise LD as described by Devlin and Risch (14 ) and determined haplotype estimation and inference using Phase v2.1.1 (15, 16 ) . We examined haplotype distributions between cases and controls by permutation test. In addition, we examined the relationship between haplotypes and incident VTE using a haplotype-based logistic regression analysis (17 ) , adjusting for the same potential risk factors.
All analyses were carried out using SAS/Genetics 9.1 package (SAS Institute Inc.). For each odds ratio, we calculated 95% CIs. A 2-tailed P value of 0.05 was considered statistically significant.
Results
ARTERIAL EVENTS
Baseline characteristics of the study participants are shown in Table 1 . As expected, the case participants had a higher prevalence of traditional cardiovascular risk factors at baseline compared with controls. Genotype frequencies for the polymorphisms tested in the subcohort group were in Hardy-Weinberg equilibrium.
Using a marker-by-marker approach, genotype and allele distributions were similar between cases and controls ( Table 2) . Results from the adjusted Cox regression analysis showed no evidence for an association of the variants tested with total CVD events, MI, or ischemic stroke (Table 3) . Overall, the variants were in strong pairwise LD (DЈ ϭ 0.95), and similar haplotype distribution was observed between cases and subcohort controls (see Supplementary Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol54/ issue5). Further analysis using a haplotype-based approach again yielded similar null findings (see Supplementary Table 2 in the online Data Supplement). 
VENOUS EVENTS
Baseline characteristics of the sample populations are shown in Table 4 . As expected, the case participants had a higher prevalence of BMI at baseline compared with subcohort controls. Genotype frequencies for the polymorphisms tested in the control/subcohort group were in Hardy-Weinberg equilibrium.
Using a marker-by-marker approach, genotype and allele distributions for Ϫ921CϾT were significantly different between cases and subcohort controls in women (Table 5 ), but not men. Results from the adjusted regression analysis showed an association of Ϫ921CϾT with increased risk of VTE (additive: HR 1.86, 95% CI 1.17-2.92, P ϭ 0.008; Table 6 ). However, no association of rs3850641 with VTE risk was found ( Table 6) . As previously described, the WHS sample population consisted of nonsmokers. We thus reran the entire regression analysis limited to nonsmokers in the PHS nested case-control sample population for direct comparison. Similar null findings were obtained in men ( Table 6 ). The polymorphisms tested were in strong pairwise LD (PHS: DЈ ϭ 1.00; WHS: DЈ ϭ 1.00). Again, the haplotype distribution was significantly different between cases and subcohort controls in women, but not men (see Supplementary Table 3 Table 4 ). Again, in an analysis limited to nonsmokers, no significant association of the haplotypes examined with risk of VTE was detected in men (see Supplementary Table  4 in the online Data Supplement). Furthermore, additional adjustment for factor V Leiden and prothrombin-mutation carrier status showed similar null (PHS) and significant (WHS) findings (data not shown).
Discussion
Our data indicate no relationship between 2 genetic variants in TNFSF4 and risk of future cardiovascular events in apparently healthy women. Thus, the result of our study does not support previous studies associating SNPs in TNFSF4 with atherothrombotic disease (1, 18 ) . The WHS study differs from previous cardiovascular case-control studies targeting TNFSF4 variants in some aspects. The most important is that the WHS study enrolled individuals with distinct socioeconomic status (health professionals) and excluded smoking individuals and HRT users. Therefore, a cardiovascular risk conferred by gene-environment interactions between TNFSF4 variants and risk factors related with lifestyle would not be detectable in the present WHS study. Gene-environment interactions have been suggested to underlie a considerable part of the variability observed at quantitative trait loci and may thus substantially influence genotype-disease associations (19 ) . In this context, it is interesting that a recent study demonstrated association of a TNFSF4 variant with cerebrovascular disease in diabetic patients only (20 ) .
We demonstrate here, however, that the promoter variant Ϫ921CϾT in TNFSF4 is significantly associated with the risk of incident VTE in women, but not men. To the best of our knowledge, the present investigation is the first to examine specific TNFSF4 variants with risk of incident VTE in men and women. Thus, the present findings implicate a relative differential contribution of traditional risk factors between arterial and Less is known of the relationship between chronic inflammation and future VTE risk. Interaction between Ox40 on T cells and Ox40L on vascular endothelial cells induces the production of RANTES (regulated on activation, normal T expressed and secreted), which recruits more T cells to the endothelium, thereby promoting a local proinflammatory state (22 ) . The present data further highlight the potential involvement of inflammation in the pathogenesis of VTE in addition to the commonly perceived coagulation and fibrinolytic mechanisms (23) (24) (25) .
The use of 2 closed population sampling schemesnested case-control and case-cohort-in which subsequent case status was determined solely by the development of disease, strongly reduces the possibility that our findings are due to bias. In essence, a case-cohort study is comparable to a case-control study in which every person in the source population has the same chance of being included as a control, regardless of how much time that person has contributed to the persontime experience of the cohort (26 ) . Although a recent simulation study with respect to analysis and efficiency suggested that a case-cohort sampling from the full cohort may be more efficient than using a comparable nested case-control design (13 ) , in many instances there may be little difference between the 2 schemes (13, 26 ) . Our study cohorts consist entirely of white subjects with distinct socioeconomic status (healthcare professionals), so our data cannot be generalized to other ethnic groups and other populations. Of note, functional analyses of both genetic variants examined in the present study, using haplotype-specific chromatin immunoprecipitation of activated polymerase II as a measure of transcriptional activity in vivo and electromobility shift assay to analyze allele-specific binding of transcription factors in vitro, have indicated that the Ϫ921CϾT polymorphism is functionally important (27 ) .
In our study, based on the present case-cohort size and the observed allele frequencies and assuming 80% power and an ␣ value of 0.05, we had the ability to detect a risk ratio (for total incident CVD events) of equal or Ͼ1.8 and of 1.5 for the Ϫ921CϾT and rs3850641 variants, respectively, assuming an additive model. Power will be less for other individual clinical endpoints. Thus, we cannot rule out that a modest risk of cardiovascular disease was associated with the polymorphisms/haplotypes tested in this study population.
Future molecular genetics studies targeting the Ox40-Ox40L pathway will need to address issues of gene-environment interactions and moderate effect sizes and investigate several related clinical phenotypes, which will determine the usefulness of TNFSF4 variants in the prediction of future thromboembolic risk.
In conclusion, the present investigation provides no evidence for an association of TNFSF4 variation with incident CVD in women, which is in contrast to previous findings. However, an association of a TNFSF4 promoter gene variant with an increased risk of incident VTE was found in women but not men. More importantly, our present findings require replication/confirmation in other prospective studies. 
